(0.31%) 5 115.55 points
(0.31%) 38 358 points
(0.34%) 15 982 points
(-0.87%) $83.12
(5.77%) $2.03
(0.38%) $2 356.20
(0.50%) $27.67
(4.05%) $959.45
(-0.22%) $0.933
(-0.39%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $4.06
発行日: 13 2月 2024 @ 06:00
リターン: 0.12%
Live Chart Being Loaded With Signals
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...
Stats | |
---|---|
本日の出来高 | 677 694 |
平均出来高 | 849 600 |
時価総額 | 181.50M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $0 ) 2024-05-11 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.03 |
ATR14 | $0.0670 (1.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Yi Kathy | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Yi Kathy | Sell | 99 634 | Stock Option (Right to Buy) |
2024-02-14 | Stein Steven H | Sell | 3 250 | Restricted Stock Units |
2024-02-14 | Orbimed Advisors Llc | Sell | 650 600 | Common Stock |
2024-02-14 | Hayden Donald J Jr | Sell | 10 000 | Common Stock |
INSIDER POWER |
---|
-12.61 |
Last 94 transactions |
Buy: 24 821 782 | Sell: 19 785 944 |
ボリューム 相関
Theseus Pharmaceuticals, 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Theseus Pharmaceuticals, 相関 - 通貨/商品
Theseus Pharmaceuticals, 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2022 |
収益: | $0 |
総利益: | $-438 000 (0.00 %) |
EPS: | $-1.220 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.84 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.010 |
Financial Reports:
No articles found.
Theseus Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.55 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.238 | 1.200 | -7.94 | -9.52 | [0 - 0.3] |
returnOnEquityTTM | -0.245 | 1.500 | -3.83 | -5.75 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 29.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 29.29 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.70 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0156 | -1.500 | 9.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 88.35 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.567 | -1.134 | [0 - 20] |
debtEquityRatioTTM | 0.0163 | -1.500 | 9.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -13.58 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.984 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.19 | 1.000 | -0.423 | 0 | [1 - 100] |
returnOnEquityTTM | -0.245 | 2.50 | -2.46 | -5.75 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.134 | 2.00 | -0.378 | -1.134 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.133 | 2.00 | -0.378 | -0.755 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00632 | 1.500 | -3.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.553 |
Theseus Pharmaceuticals,
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。